Can these high-flying biotech stocks keep the momentum going?
News & Analysis: Adverum Biotechnologies, Inc.
The gene therapy developer has dropped its most advanced clinical trial.
The small biopharma announced the departure of both its CEO and CMO.
Growth stocks can hail from all sorts of industries, but sometimes you have to know what you're looking for.
The ongoing gene therapy revolution could send these three biotech stocks soaring. Here's what you need to know right now.
These biotech stocks jumped by 35% or more over the last few days. But can their momentum continue?
This under-the-radar biotech stock has now doubled in the past month, thanks to the gene-therapy gold rush.
Avalanche Biotechnologies surprised the market with its second-quarter earnings release after the bell yesterday. Unfortunately, the report contained a bombshell regarding the future of its most advanced clinical candidate. Here's what investors need to know moving forward.
Avalanche and Puma Biotechnology have seen their share prices plummet in 2015. Are either of these cratering biotechs worth the risk?
Avalanche Biotechnologies saw its share price plummet today on exceptional volume. Here's why.